Top Page
Tonix Pharma
(NASDAQ:TNXP)
Tonix Pharma (TNXP) vs. SPDR S&P 500 ETF (SPY)
Tonix Pharma Business Overview & Revenue Model
Tonix Pharma Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.30M | 10.09M | 7.77M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.53M | 2.33M | 3.03M | 0.00 | 0.00 | -27.00K |
| EBITDA | -97.31M | -74.32M | -114.09M | -110.84M | -92.26M | -50.44M |
| Net Income | -99.22M | -130.04M | -116.66M | -110.22M | -92.29M | -50.46M |
Balance Sheet | ||||||
| Total Assets | 252.44M | 162.89M | 154.46M | 225.69M | 240.90M | 98.18M |
| Cash, Cash Equivalents and Short-Term Investments | 190.06M | 98.78M | 24.95M | 120.23M | 178.66M | 77.07M |
| Total Debt | 425.00K | 5.30M | 9.81M | 760.00K | 956.00K | 1.31M |
| Total Liabilities | 21.30M | 23.33M | 48.93M | 18.51M | 22.18M | 10.54M |
| Stockholders Equity | 231.14M | 139.56M | 105.53M | 207.18M | 218.72M | 87.65M |
Cash Flow | ||||||
| Free Cash Flow | -78.33M | -61.05M | -109.90M | -146.20M | -110.86M | -57.13M |
| Operating Cash Flow | -74.82M | -60.92M | -102.00M | -98.05M | -75.56M | -48.57M |
| Investing Cash Flow | -3.51M | -120.00K | -29.07M | -48.15M | -35.31M | -8.56M |
| Financing Cash Flow | 240.54M | 134.87M | 36.52M | 87.84M | 212.49M | 123.11M |
Tonix Pharma Technical Analysis
Tonix Pharma Risk Analysis
Tonix Pharma Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $139.13M | 25.04 | 12.64% | ― | 35.42% | ― | |
55 Neutral | $318.43M | ― | -174.79% | ― | -76.59% | 94.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $179.24M | ― | -64.99% | ― | -8.79% | 81.36% | |
50 Neutral | $124.58M | -0.82 | -52.35% | ― | -46.92% | 20.26% | |
49 Neutral | $177.86M | ― | -271.32% | ― | -75.77% | -31.24% | |
36 Underperform | $135.64M | -1.37 | -110.72% | ― | ― | 77.08% |
Tonix Pharma Corporate Events
On December 9, 2025, Tonix Pharmaceuticals announced the appointment of Irina Ishak as General Counsel. Ms. Ishak, with over 25 years of experience in the life sciences industry, will lead the company’s legal, corporate governance, and compliance functions. Her appointment is expected to support Tonix’s commercialization efforts and strategic growth, particularly following the recent FDA approval of their fibromyalgia treatment, TONMYA.
On November 24, 2025, Tonix Pharmaceuticals announced that the FDA cleared their IND application for TNX-102 SL, a sublingual tablet designed to treat major depressive disorder in adults. The clearance allows the company to proceed with the Phase 2 HORIZON study, a 6-week trial involving 360 patients across 30 U.S. sites, comparing TNX-102 SL to a placebo. This development marks a significant step in Tonix’s clinical development efforts and could impact their market positioning by addressing unmet needs in MDD treatment.
On November 21, 2025, Tonix Pharmaceuticals amended its Sales Agreement with A.G.P./Alliance Global Partners to increase the maximum aggregate offering price of shares from $150 million to $400 million. This amendment allows Tonix to potentially raise more capital, which could enhance its operational capabilities and strengthen its market position.
On November 18, 2025, Tonix Pharmaceuticals Holding Corp. announced that its Board of Directors approved an increase to its share repurchase program. The company may now repurchase up to an additional $25 million in value of its outstanding common stock, raising the total authorized shares under the program to $35 million.
On November 17, 2025, Tonix Pharmaceuticals announced that its product, TONMYATM (cyclobenzaprine HCl sublingual tablets), is now commercially available by prescription in U.S. pharmacies. This development marks a significant step for the company, potentially enhancing its market presence and offering new treatment options for patients, thereby impacting stakeholders positively.
On October 22, 2025, Tonix Pharmaceuticals announced that the first patient was dosed in the FOCUS study at Massachusetts General Hospital, targeting adult patients with arginine-vasopressin deficiency (AVP-D). The study is a randomized, double-blind, placebo-controlled crossover pilot designed to evaluate the company’s intranasal potentiated oxytocin products, TNX-2900 and TNX-1900, on markers of anxiety, depression, and socioemotional functioning. This trial aims to generate preliminary data for future studies on oxytocin replacement therapy, potentially impacting the treatment landscape for AVP-D and improving patient quality of life.
Tonix Pharmaceuticals announced plans to initiate a Phase 2 trial of its TNX-102 SL product candidate for major depressive disorder in 2026, and an adaptive Phase 2/3 study of TNX-4800 for the seasonal prevention of Lyme disease in 2027. These developments are part of the company’s strategic efforts to expand its clinical pipeline and strengthen its position in the pharmaceutical market.
On September 30, 2025, Tonix Pharmaceuticals announced the appointment of Ganesh Kamath as Head of Market Access, effective September 29, 2025. The company also established the wholesale acquisition cost for Tonmya™, setting it at $1,860 per month for a 60-count supply for adults, and $930 per month for a 30-count supply for geriatric patients and adults with mild hepatic impairment.
On September 29, 2025, Tonix Pharmaceuticals announced plans to advance its TNX-2900 program for Prader-Willi syndrome into a Phase 2 clinical trial. The trial will assess the safety, tolerability, and efficacy of TNX-2900 in children aged 8 to 17.5 years, with the study expected to start in 2026. This development marks a significant step in Tonix’s efforts to address rare diseases, potentially enhancing its market position and offering new treatment options for stakeholders.
On September 18, 2025, Tonix Pharmaceuticals announced the completion of a Type B Pre-IND meeting with the FDA for its TNX-102 SL product candidate aimed at treating major depressive disorder. The FDA’s feedback was positive, suggesting that the proposed long-term safety data collection plan is reasonable, which may streamline the development path. Tonix plans to file an Investigational New Drug application in the fourth quarter of 2025 and expects to enter Phase 2 clinical trials soon after, potentially expanding the therapeutic indications of TNX-102 SL.
On September 17, 2025, Tonix Pharmaceuticals announced the in-licensing of worldwide rights to TNX-4800, a long-acting human monoclonal antibody targeting Lyme disease. Developed by UMass Chan Medical School, TNX-4800 offers a novel approach by providing pre-exposure prophylaxis against Lyme disease with a single subcutaneous administration, bypassing the need for multidose vaccines. This strategic move positions Tonix to advance TNX-4800 through clinical trials, aiming for a Biologics Licensing Application submission to the FDA, potentially impacting the market for Lyme disease prevention.